Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05263206

Efficacy and Safety of Subcutaneous Dupilumab for the Treatment of Adult Participants With Chronic Pruritus of Unknown Origin (CPUO) (LIBERTY-CPUO-CHIC)

The main objective of the study is to assess efficacy and safety of dupilumab given up to 24 weeks in adults with CPUO.

This is a master protocol which includes 2 parallel-treatment, double-blind, 2- arm Phase 3 staggered studies of similar design (Study A and Study B) in male and female participants aged 18 to 90 years with CPUO. Study B design was to be adapted based on the results of Study A.

For both Study A and B, after an up-to-4-week screening period, participants with severe pruritus (worst-itch numerical rating scale [WI-NRS ≥7) will enter a 4-week run-in period and will be treated with a non-sedative antihistamine and an emollient (moisturizer). Participants with severe pruritus (WI-NRS ≥7) at baseline will be randomized (1:1) to be treated for 24 weeks with either dupilumab or matching placebo in addition to their non-sedative antihistamine and emollient regimen. The treatment period for both study A and B will be followed by a 12-week follow-up period.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Pruritus Pathological Conditions, Signs and Symptoms Signs and Symptoms Skin Diseases Skin Manifestations Skin and Connective Tissue Diseases

Age range

18 year–90 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Investigational Site Number : 0320004, Rosario, Santa Fe Province, Argentina

Loading trial locations.

About this study

Study duration per participant will be up to 44 weeks for both Study A and Study B.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Participant must be 18 (or the legal age of consent in the jurisdiction in which the study is taking place) to 90 years of age inclusive, at the time of signing the informed consent.
  • Participants with chronic pruritus for at least 6 months before the screening visit.
  • Chronic pruritus considered of unknown origin as assessed by the investigator at baseline (excluding chronic pruritus secondary to dermatological or systemic conditions, of neuropathic or psychogenic origin or secondary to drugs).
  • Chronic pruritus must affect at least 2 of the following body areas: legs, arms, or trunk.
  • History of insufficient control of the chronic pruritus with prior treatment.
  • Participants should receive optimal treatment for concomitant conditions that could impact pruritus (eg, diabetes, iron deficiency).
  • Participants must have a history of severe itch and a worst itch score of ≥7 at screening on the WI-NRS (score scale ranges from 0 to 10; higher score indicates worse itch) and Patient Global Impression of Severity (PGIS) of pruritus scored "severe" at screening.
  • Participants must have an average worst itch score of ≥7 in the 7 days prior to run-in visit and in the 7 days prior to Day 1 on the WI-NRS.
  • Participants scored "severe" in the PGIS of pruritus on Day 1.

Exclusion criteria

Participants are excluded from the study if any of the following criteria apply:

  • Severe concomitant illness(es) that, in the Investigator's judgment, would adversely affect the patient's participation in the study.
  • Patients with active tuberculosis or non-tuberculous mycobacterial infection, or a history of incompletely treated tuberculosis, unless it is well documented by a specialist that the participant has been adequately treated and can now start treatment with a biologic agent.
  • Diagnosed with, suspected of, or at high risk of endoparasitic infection, and/or use of antiparasitic drug within 2 weeks before the screening visit.
  • HIV infection.
  • Severe renal failure (dialysis).
  • Active chronic or acute infection requiring treatment with systemic antibiotics, antivirals, or antifungals within 2 weeks before the run-in visit.
  • Known or suspected immunodeficiency.
  • Active malignancy or history of malignancy within 5 years before the baseline visit, except completely treated in situ carcinoma of the cervix and completely treated and resolved non metastatic squamous or basal cell carcinoma of the skin.
  • History of hypersensitivity or intolerance to non-sedative antihistamines.
  • Participation in prior dupilumab clinical study or have been treated with commercially available dupilumab.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Treatment and study plan

Dupilumab

Drug

Injection solution subcutaneous

Placebo

Drug

Injection solution SC

Fexofenadine (loratadine if not available)

Drug

Tablet or capsule Oral

Primary outcomes

  1. Study A: Proportion of participants with improvement (reduction) in weekly average of daily worst-itch numerical rating scale (WI-NRS) by ≥4 from baseline to Week 24

    Time frame: Baseline to Week 24

    WI-NRS is a patient reported outcome (PRO) comprised of a single item rated on a scale from 0 ("No itch") to 10 ("Worst imaginable itch").

  2. Study B: Proportion of participants with improvement (reduction) in weekly average of daily WI-NRS by ≥4 from baseline to Week 12

    Time frame: Baseline to Week 12

    WI-NRS is a PRO comprised of a single item rated on a scale from 0 ("No itch") to 10 ("Worst imaginable itch").

Secondary outcomes

  1. Study A; Proportion of participants with improvement (reduction) in weekly average of daily WI-NRS by ≥4 from baseline to Week 12

    Time frame: Baseline to Week 12

    WI-NRS is a PRO comprised of a single item rated on a scale from 0 ("No itch") to 10 ("Worst imaginable itch").

  2. Study A: Proportion of participants who scored "none" or "mild" in Patient Global Impression of Severity (PGIS) of pruritus at Week 24

    Time frame: Week 24

    The PGIS of pruritus is a one-item categorical scale that asks participants to provide the overall self-assessment of their pruritus severity on a 4-point scale for the past week. Response choices are: "None", "Mild", "Moderate", "Severe".

  3. Study A: Proportion of participants with improvement (reduction) in weekly average of daily WI-NRS by ≥4 from baseline over time until Week 24

    Time frame: Baseline to Week 24

    WI-NRS is a PRO comprised of a single item rated on a scale from 0 ("No itch") to 10 ("Worst imaginable itch").

  4. Study A: Time to first response of WI-NRS ≥4 points reduction from baseline by Week 24

    Time frame: Baseline to Week 24

    WI-NRS is a PRO comprised of a single item rated on a scale from 0 ("No itch") to 10 ("Worst imaginable itch").

  5. Study A: Absolute change from baseline in weekly average of daily WI-NRS at Week 24

    Time frame: Baseline to Week 24

    WI-NRS is a PRO comprised of a single item rated on a scale from 0 ("No itch") to 10 ("Worst imaginable itch").

  6. Study A: Percent change from baseline in weekly average of daily WI-NRS at Week 24

    Time frame: Baseline to Week 24

    WI-NRS is a PRO comprised of a single item rated on a scale from 0 ("No itch") to 10 ("Worst imaginable itch").

  7. Study A: Proportion of participants who scored "none" or "mild" in PGIS of pruritus at Week 12

    Time frame: Week 12

    The PGIS of pruritus is a one-item categorical scale that asks participants to provide the overall self-assessment of their pruritus severity on a 4-point scale for the past week. Response choices are: "None", "Mild", "Moderate", "Severe".

  8. Study A: Absolute change from baseline in weekly average of daily WI-NRS at Week 12

    Time frame: Baseline to Week 12

    WI-NRS is a PRO comprised of a single item rated on a scale from 0 ("No itch") to 10 ("Worst imaginable itch").

  9. Study A: Percent change from baseline in weekly average of daily WI-NRS at Week 12

    Time frame: Baseline to Week 12

    WI-NRS is a PRO comprised of a single item rated on a scale from 0 ("No itch") to 10 ("Worst imaginable itch").

  10. Study A: Absolute change from baseline in weekly average of daily sleep disturbance numerical rating scale (NRS) at Week 24

    Time frame: Baseline to Week 24

    The sleep disturbance NRS is to be used by the participants to report the degree of their sleep loss related to itch over the past 24 hours. Participants will rate their sleep disturbance from 0 ('no sleep loss related to itch') to 10 ('I cannot sleep at all due to itch') once daily in the morning.

  11. Study A: Percent change from baseline in weekly average of daily sleep disturbance NRS at Week 24

    Time frame: Baseline to Week 24

    The sleep disturbance NRS is to be used by the participants to report the degree of their sleep loss related to itch over the past 24 hours. Participants will rate their sleep disturbance from 0 ('no sleep loss related to itch') to 10 ('I cannot sleep at all due to itch') once daily in the morning.

  12. Study A: Change from baseline in Dermatology Life Quality Index (DLQI) score at Week 24

    Time frame: Baseline to Week 24

    The DLQI is a validated 10-item questionnaire to measure dermatology-specific quality of life (QoL) in adult patients. Overall scoring ranges from 0 to 30, with a higher score indicating a poorer QoL.

  13. Study A: Change from baseline in the Itchy quality of life (ItchyQoL) score at Week 24

    Time frame: Baseline to Week 24

    ItchyQoL is a pruritus-specific QoL instrument that measures specifically disease burden in pruritus patients.

  14. Study A: Change from baseline in Hospital Anxiety and Depression Scale (HADS) total score at Week 24

    Time frame: Baseline to Week 24

    The HADS is a validated questionnaire for screening anxiety and depression in non-psychiatric populations. The total score ranges from 0 to 42. 0 to 7= normal; 8 to 10= borderline abnormal; 11 to 21= abnormal.

  15. Study A: Absolute change from baseline in weekly average of daily sleep disturbance NRS at Week 12

    Time frame: Baseline to Week 12

    The sleep disturbance NRS is to be used by the participants to report the degree of their sleep loss related to itch over the past 24 hours. Participants will rate their sleep disturbance from 0 ('no sleep loss related to itch') to 10 ('I cannot sleep at all due to itch') once daily in the morning.

  16. Study A: Percent change from baseline in weekly average of daily sleep disturbance NRS at Week 12

    Time frame: Baseline to Week 12

    The sleep disturbance NRS is to be used by the participants to report the degree of their sleep loss related to itch over the past 24 hours. Participants will rate their sleep disturbance from 0 ('no sleep loss related to itch') to 10 ('I cannot sleep at all due to itch') once daily in the morning.

  17. Study A: Change from baseline in DLQI score at Week 12

    Time frame: Baseline to Week 12

    The DLQI is a validated 10-item questionnaire to measure dermatology-specific quality of life (QoL) in adult patients. Overall scoring ranges from 0 to 30, with a higher score indicating a poorer QoL.

  18. Study A: Change from baseline in the ItchyQoL score at Week 12

    Time frame: Baseline to Week 12

    ItchyQoL is a pruritus-specific QoL instrument that measures specifically disease burden in pruritus patients. It is a 22-item instrument that measures the degree to which pruritus affects quality-of-life for the past week. The overall score is the average of the 22 items ranging from 1 to 5. A higher score corresponds to a more adverse impact on QoL.

  19. Study A: Change from baseline in HADS total score at Week 12

    Time frame: Baseline to Week 12

    The HADS is a validated questionnaire for screening anxiety and depression in non-psychiatric populations. The total score ranges from 0 to 42. 0 to 7= normal; 8 to 10= borderline abnormal; 11 to 21= abnormal.

  20. Study A: Percentage of participants experiencing treatment-emergent adverse events (TEAEs) or serious adverse events (SAEs) from baseline through end of study (EOS)

    Time frame: Baseline to Week 36

    Percentage of participants experiencing TEAEs or SAEs from baseline through EOS

  21. Study A: Incidence of treatment-emergent antidrug antibodies (ADA) against dupilumab

    Time frame: Baseline to Week 36

    Incidence of treatment-emergent ADA against dupilumab

  22. Study B: Proportion of participants who scored "none" or "mild" in PGIS of pruritus at Week 24

    Time frame: Week 24

    The PGIS of pruritus is a one-item categorical scale that asks participants to provide the overall self-assessment of their pruritus severity on a 4-point scale for the past week. Response choices are: "None", "Mild", "Moderate", "Severe".

  23. Study B: Proportion of participants who scored "none" or "mild" in PGIS of pruritus at Week 12

    Time frame: Week 12

    The PGIS of pruritus is a one-item categorical scale that asks participants to provide the overall self-assessment of their pruritus severity on a 4-point scale for the past week. Response choices are: "None", "Mild", "Moderate", "Severe".

  24. Study B: Absolute change from baseline in weekly average of daily WI-NRS at Week 12

    Time frame: Baseline to Week 12

    WI-NRS is a PRO comprised of a single item rated on a scale from 0 ("No itch") to 10 ("Worst imaginable itch").

  25. Study B: Percent change from baseline in weekly average of daily WI-NRS at Week 12

    Time frame: Baseline to Week 12

    WI-NRS is a PRO comprised of a single item rated on a scale from 0 ("No itch") to 10 ("Worst imaginable itch").

  26. Study B: Absolute change from baseline in weekly average of daily WI-NRS at Week 24

    Time frame: Baseline to Week 24

    WI-NRS is a PRO comprised of a single item rated on a scale from 0 ("No itch") to 10 ("Worst imaginable itch").

  27. Study B: Percentage change from baseline in weekly average of daily WI-NRS at Week 24

    Time frame: Baseline to Week 24

    WI-NRS is a PRO comprised of a single item rated on a scale from 0 ("No itch") to 10 ("Worst imaginable itch").

  28. Study B: Proportion of participants with improvement (reduction) in weekly average of daily WI-NRS by ≥4 from baseline, sustained from Week 19 through Week 24

    Time frame: Baseline to Week 19 through Week 24

    WI-NRS is a PRO comprised of a single item rated on a scale from 0 ("No itch") to 10 ("Worst imaginable itch").

  29. Study B: Proportion of participants with improvement (reduction) in weekly average of daily WI-NRS by ≥5 from baseline to Week 24

    Time frame: Baseline to Week 24

    WI-NRS is a PRO comprised of a single item rated on a scale from 0 ("No itch") to 10 ("Worst imaginable itch").

  30. Study B: Proportion of participants with improvement (reduction) in weekly average of daily WI-NRS by ≥4 from baseline to Week 24

    Time frame: Baseline to Week 24

    WI-NRS is a PRO comprised of a single item rated on a scale from 0 ("No itch") to 10 ("Worst imaginable itch").

  31. Study B: Proportion of participants with weekly average of daily WI-NRS <2 at Week 24

    Time frame: Week 24

    WI-NRS is a PRO comprised of a single item rated on a scale from 0 ("No itch") to 10 ("Worst imaginable itch").

  32. Study B: Time to first response of WI-NRS ≥4 points reduction from baseline by Week 24

    Time frame: Baseline to Week 24

    WI-NRS is a PRO comprised of a single item rated on a scale from 0 ("No itch") to 10 ("Worst imaginable itch").

  33. Study B: Proportion of participants with improvement (reduction) in weekly average of daily WI-NRS by ≥5 from baseline to Week 12

    Time frame: Baseline to Week 12

    WI-NRS is a PRO comprised of a single item rated on a scale from 0 ("No itch") to 10 ("Worst imaginable itch").

  34. Study B: Proportion of participants with weekly average of daily WI-NRS <2 at Week 12

    Time frame: Week 12

    WI-NRS is a PRO comprised of a single item rated on a scale from 0 ("No itch") to 10 ("Worst imaginable itch").

  35. Study B: Absolute change from baseline in weekly average of daily itch-related sleep disturbance NRS at Week 12 and Week 24

    Time frame: Baseline to Week 12 and Week 24

    The sleep disturbance NRS is to be used by the participants to report the degree of their sleep loss related to itch over the past 24 hours. Participants will rate their sleep disturbance from 0 ('no sleep loss related to itch') to 10 ('I cannot sleep at all due to itch') once daily in the morning.

  36. Study B: Percent change from baseline in weekly average of daily itch-related sleep disturbance NRS at Week 12 and Week 24

    Time frame: Baseline to Week 12 and Week 24

    The sleep disturbance NRS is to be used by the participants to report the degree of their sleep loss related to itch over the past 24 hours. Participants will rate their sleep disturbance from 0 ('no sleep loss related to itch') to 10 ('I cannot sleep at all due to itch') once daily in the morning.

  37. Study B: Change from baseline in DLQI score at Week 12 and Week 24

    Time frame: Baseline to Week 12 and Week 24

    The DLQI is a validated 10-item questionnaire to measure dermatology-specific quality of life (QoL) in adult patients. Overall scoring ranges from 0 to 30, with a higher score indicating a poorer QoL.

  38. Study B: Change from baseline in the ItchyQoL score at Week 12 and Week 24

    Time frame: Baseline to Week 12 and Week 24

    ItchyQoL is a pruritus-specific QoL instrument that measures specifically disease burden in pruritus patients. It is a 22-item instrument that measures the degree to which pruritus affects quality-of-life for the past week. The overall score is the average of the 22 items ranging from 1 to 5. A higher score corresponds to a more adverse impact on QoL.

  39. Study B: Change from baseline in HADS total score at Week 12 and Week 24

    Time frame: Baseline to Week 12 and Week 24

    The HADS is a validated questionnaire for screening anxiety and depression in non-psychiatric populations. The total score ranges from 0 to 42. 0 to 7= normal; 8 to 10= borderline abnormal; 11 to 21= abnormal.

  40. Study B: Percentage of participants experiencing TEAEs or SAEs from baseline through EOS

    Time frame: Baseline to Week 36

    Percentage of participants experiencing TEAEs or SAEs from baseline through EOS

  41. Study B: Incidence of treatment-emergent ADA against dupilumab

    Time frame: Baseline to Week 36

    Incidence of treatment-emergent ADA against dupilumab

Study contacts

Contact information is provided by the study sponsor or research team.

Trial Transparency email recommended (Toll free number for US & Canada)

CONTACT

[email protected]

800-633-1610 ext. option 6

Sponsors and collaborators

Lead sponsor

Sanofi

Industry

Registry information

Official study title

Master Protocol of Two Randomized, Double Blind, Placebo-controlled, Multi-center, Parallel Group Studies to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Chronic Pruritus of Unknown Origin (CPUO)

Important dates

Study start
2022
Primary completion
2027
Study completion
2027
First posted
Mar 2, 2022
Registry last updated
Jul 6, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.